Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387609626> ?p ?o ?g. }
Showing items 1 to 86 of
86
with 100 items per page.
- W4387609626 abstract "<div>AbstractPurpose:<p>This study aimed to evaluate the efficacy and safety of camrelizumab plus apatinib with or without stereotactic body radiotherapy (SBRT) as first-line therapy for patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT).</p>Patients and Methods:<p>This is a multicenter, open-label, noncomparative, randomized trial that recruited patients with HCC with type II/III/IV PVTT, who had not previously received systemic therapy. Patients were randomly assigned (2:1) to receive camrelizumab (200 mg, every 3 weeks) and apatinib (250 mg, every day) with or without SBRT [95% planning target volume (PTV), 36–40 Gy/6–8 Gy]. The primary endpoint was overall survival (OS), and the secondary endpoints were progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), duration of response, time to progression, and safety.</p>Results:<p>Sixty patients were enrolled and randomly assigned to two prospective cohorts. Median OS were 12.7 months [95% confidence interval (CI), 10.2–not available (NA)] and 8.6 months (95% CI, 5.6–NA), and median PFS were 4.6 months (95% CI, 3.3–7.0) and 2.5 months (95% CI, 2.0–7.6) for the SBRT and non-SBRT cohorts, respectively. The ORR and DCR were 47.5% and 72.5% in the SBRT cohort, and 20.0% and 40.0% in the non-SBRT cohort. The most common treatment-related adverse events of any grade were hypertension (55.0%), hand-foot syndrome (51.7%), and leukopenia (50.0%). Grade ≥ 3 was reported in 13 (21.7%) patients.</p>Conclusions:<p>First-line treatment with camrelizumab–apatinib combined with or without SBRT showed clinical benefits in patients with HCC with PVTT, with an acceptable safety profile. Thus, these combination regimens may be potential options for such patients.</p></div>" @default.
- W4387609626 created "2023-10-14" @default.
- W4387609626 creator A5005495650 @default.
- W4387609626 creator A5013500106 @default.
- W4387609626 creator A5014092860 @default.
- W4387609626 creator A5015919681 @default.
- W4387609626 creator A5016326991 @default.
- W4387609626 creator A5021045596 @default.
- W4387609626 creator A5034473067 @default.
- W4387609626 creator A5037883310 @default.
- W4387609626 creator A5053013509 @default.
- W4387609626 creator A5053206297 @default.
- W4387609626 creator A5054081137 @default.
- W4387609626 creator A5065972394 @default.
- W4387609626 creator A5087527641 @default.
- W4387609626 creator A5088024792 @default.
- W4387609626 creator A5089170314 @default.
- W4387609626 date "2023-10-13" @default.
- W4387609626 modified "2023-10-14" @default.
- W4387609626 title "Data from Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus" @default.
- W4387609626 doi "https://doi.org/10.1158/1078-0432.c.6879420.v1" @default.
- W4387609626 hasPublicationYear "2023" @default.
- W4387609626 type Work @default.
- W4387609626 citedByCount "0" @default.
- W4387609626 crossrefType "posted-content" @default.
- W4387609626 hasAuthorship W4387609626A5005495650 @default.
- W4387609626 hasAuthorship W4387609626A5013500106 @default.
- W4387609626 hasAuthorship W4387609626A5014092860 @default.
- W4387609626 hasAuthorship W4387609626A5015919681 @default.
- W4387609626 hasAuthorship W4387609626A5016326991 @default.
- W4387609626 hasAuthorship W4387609626A5021045596 @default.
- W4387609626 hasAuthorship W4387609626A5034473067 @default.
- W4387609626 hasAuthorship W4387609626A5037883310 @default.
- W4387609626 hasAuthorship W4387609626A5053013509 @default.
- W4387609626 hasAuthorship W4387609626A5053206297 @default.
- W4387609626 hasAuthorship W4387609626A5054081137 @default.
- W4387609626 hasAuthorship W4387609626A5065972394 @default.
- W4387609626 hasAuthorship W4387609626A5087527641 @default.
- W4387609626 hasAuthorship W4387609626A5088024792 @default.
- W4387609626 hasAuthorship W4387609626A5089170314 @default.
- W4387609626 hasConcept C126322002 @default.
- W4387609626 hasConcept C126894567 @default.
- W4387609626 hasConcept C141071460 @default.
- W4387609626 hasConcept C143998085 @default.
- W4387609626 hasConcept C168563851 @default.
- W4387609626 hasConcept C197934379 @default.
- W4387609626 hasConcept C203092338 @default.
- W4387609626 hasConcept C2776694085 @default.
- W4387609626 hasConcept C2778019345 @default.
- W4387609626 hasConcept C2780668389 @default.
- W4387609626 hasConcept C2780739268 @default.
- W4387609626 hasConcept C44249647 @default.
- W4387609626 hasConcept C509974204 @default.
- W4387609626 hasConcept C71924100 @default.
- W4387609626 hasConcept C72563966 @default.
- W4387609626 hasConceptScore W4387609626C126322002 @default.
- W4387609626 hasConceptScore W4387609626C126894567 @default.
- W4387609626 hasConceptScore W4387609626C141071460 @default.
- W4387609626 hasConceptScore W4387609626C143998085 @default.
- W4387609626 hasConceptScore W4387609626C168563851 @default.
- W4387609626 hasConceptScore W4387609626C197934379 @default.
- W4387609626 hasConceptScore W4387609626C203092338 @default.
- W4387609626 hasConceptScore W4387609626C2776694085 @default.
- W4387609626 hasConceptScore W4387609626C2778019345 @default.
- W4387609626 hasConceptScore W4387609626C2780668389 @default.
- W4387609626 hasConceptScore W4387609626C2780739268 @default.
- W4387609626 hasConceptScore W4387609626C44249647 @default.
- W4387609626 hasConceptScore W4387609626C509974204 @default.
- W4387609626 hasConceptScore W4387609626C71924100 @default.
- W4387609626 hasConceptScore W4387609626C72563966 @default.
- W4387609626 hasLocation W43876096261 @default.
- W4387609626 hasOpenAccess W4387609626 @default.
- W4387609626 hasPrimaryLocation W43876096261 @default.
- W4387609626 hasRelatedWork W1666348496 @default.
- W4387609626 hasRelatedWork W1987273470 @default.
- W4387609626 hasRelatedWork W2142415310 @default.
- W4387609626 hasRelatedWork W2536995545 @default.
- W4387609626 hasRelatedWork W2910926762 @default.
- W4387609626 hasRelatedWork W3013928771 @default.
- W4387609626 hasRelatedWork W4224304085 @default.
- W4387609626 hasRelatedWork W4229452767 @default.
- W4387609626 hasRelatedWork W4295828468 @default.
- W4387609626 hasRelatedWork W4385538113 @default.
- W4387609626 isParatext "false" @default.
- W4387609626 isRetracted "false" @default.
- W4387609626 workType "article" @default.